Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)

European Journal of Cancer

Volumn 34, Issue 7, 1998, Pages 1124-1127

  Monnet, I ^a   Brienza, S ^b   Hugret, F ^b   Voisin, S ^c   Gastiaburu, J ^b   Saltiel, J C ^c   Soulie P ^d   Armand, J P ^e   Cvitkovic, E ^d   De Cremoux, H ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Debiopharm France ^*  (France)

^c CENTRE HOSPITALIER   (France)

^d HÔPITAL PAUL BROUSSE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Non small cell lung cancer; Oxaliplatin chemotherapy

Indexed keywords

OXALIPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; DYSESTHESIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUMOR BIOPSY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032103861     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00007-0     Document Type: Article

References (15)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1996, 311, 899-909.
2. Mathé G, Kidani Y, Sekiguchi M, et al. Oxalato-platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother 1989, 43, 237-250.
3. Extra J.M., Espie M., Calvo F., Ferme C., Mignot L., Marty M. Phase I study of Oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 25:1990;299-303.
4. Mathé G, Kidani Y, Triana K, et al. Phase I trial of trans 1 diaminocyclohexane oxalato-platinium (L-OHP). Biomed Pharmacother 1986, 40, 372-376.
5. Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of Oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990, 82, 1046-1050.
6. Lévi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous infusion at circadian rhythm-modulated rate. Eur J Cancer 1993, 29A, 1284-1293.
7. Lévi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994, 86, 1608-1617.
8. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who where resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7, 95-98.
9. Chollet P., Bensmaine M.A., Brienza S. Single agent activity in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol. 7:1996;1065-1070.
10. Gastiaburu J, Brienza S, Rotarski M, et al. Oxaliplatin (L-OHP): a new platinum analog active in refractory/relapsed intermediate and low grade NHL. A phase II study. Eur J Cancer 1993, 29A(Suppl. 6): abstr 980.
11. Degardin M., Cappelaere P., Krakowski L., Fargeot P., Cuppissol D., Brienza S. Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer Oral Oncol. 32B:(4):1996;278-279.
12. Miller V.A., Rigas J.R., Grant S.C., Pisters K.M., Kris M.G. New chemotherapeutic agents for non-small cell lung cancer. Chest. 107:(Suppl. 6):1995;306S-311S.
13. Kriss M, Cohen E, Gralla R. An analysis of 134 phase II trials in non small cell lung cancer. Proceedings of the IV World Conference on Lung Cancer. Toronto, 1985, 133.
14. Bunn P.A. Jr. Clinical experiences with carboplatin (paraplatin) in lung cancer. Semin Oncol. 19:(Suppl. 2):1992;1-11.
15. Mollman J.E. Cisplatin neurotoxicity. N Engl J Med. 322:1990;126-127.